陈述祥;刘彦;区文欢;陈丽君;

• 1:暨南大学附属江门中医院
• 2:广东江门市五邑中医院骨伤科二区
• 3:暨南大学附属江门中医院
• 4:广东江门市五邑中医院

摘要(Abstract)：

[目的]探讨阿哌沙班和依诺肝素对老年股骨粗隆间骨折PFNA内固定术后血液流变学的影响。[方法]前瞻性收集暨南大学附属江门中医院行闭合复位PFNA内固定治疗的老年股骨粗隆间骨折患者68例,随机分为阿哌沙班组和伊诺肝素组,每组34例。所有患者均在腰硬联合麻醉下进行手术,记录所有患者术中及术后第1、2 d的输液量、出血量及尿量,术前和术后第1周两组患者的血液流变学指标。[结果]阿哌沙班组术后第1周的血浆黏度、红细胞比容、红细胞变形指数、血浆纤维蛋白原水平与术前相比差异无统计学意义(P>0.05),伊诺肝素组在术后第1周的血浆黏度、红细胞变形指数、血浆纤维蛋白原水平均显著高于伊诺肝素组术前水平和阿哌沙班组术后水平,差异有统计学意义(P<0.05)。[结论]对于老年股骨粗隆间骨折行闭合复位PFNA内固定术的患者,阿哌沙班较依诺肝素更有利于血液流变学指标的改善,可作为减少术后血栓性并发症的有效措施之一。

关键词(KeyWords)： 股骨粗隆间骨折;血液流变学;阿哌沙班;依诺肝素

Abstract:

Keywords:

基金项目(Foundation): 江门市科技计划项目(编号:[2014]73-6号)

作者(Author): 陈述祥;刘彦;区文欢;陈丽君;

Email:

DOI:

参考文献(References)：

• [1]Klop C,Welsing PM,Cooper C,et al.Mortality in British hip fracture patients,2000-2010:a population-based retrospective cohort study[J].Bone,2014,66(2):171-177.
• [2]Vidan MT,Sanchez E,Gracia Y,et al.Causes and effects of surgical delay in patients with hip fracture:a cohort study[J].Ann Intern Med,2011,155(4):226-233.
• [3]Beksac B,Gonzalez-Delia-valle A,Salvati EA.Thromboembolic disease after total hip arthroplasty:who is at risk[J].Clin Orthop,2006,453(453):211-224.
• [4]Roche JJ,Wenn RT,Sahota O,et al.Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people:prospective observational cohort study[J].BMJ,2005,331(7529):1374.
• [5]Carpintero P,Caeiro JR,Carpintero R,et al.Complications of hip fractures:a review[J].World J Orthop,2014,5(4):402-411.
• [6]周剑鹏,夏虹.活血益气补肾方对老年髋关节置换术后血液流变学参数及e NOS活性的影响[J].中国病理生理学杂志,2015,31(5):934-942.
• [7]Prensky C,Urruela A,Guss MS,et al.Symptomatic venous thromboembolism in low-energy isolated fractures in hospitalised patients[J].Injury,2013,44(8):1135-1139.
• [8]Niikura T,Lee SY,Oe K,et al.Incidence of venous thromboembolism in pelvic and acetabular fractures in the Japanese population[J].J Orthop Sci,2012,17(3):233-238.
• [9]Bateman L,Vuppala S,Porada P,et al.Medical management in the acute hip fracture patient:a comprehensive review for the internist[J].Ochsner J,2012,12(2):101-110.
• [10]Gómez-Cerezo JF,Gómez-Arrayás I,Suárez-Fernández C,et al.Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement[J].Rev Esp Cir Ortop Traumatol,2012,56(6):459-470.
• [11]Zhou H,Wang L,Wu X,et al.Validation of a venous thromboembolism risk assessment model in hospitalized Chinese patients:a case-control study[J].J Atheroscler Thromb,2014,21(3):261-272.
• [12]陈述祥,刘彦,区文欢,等.老年髋部骨折术后肺部并发症的危险因素分析[J/CD].中华老年骨科与康复电子杂志,2016,2(4):239-244.
• [13]李虎,王健,肖军,等.比较磺达肝葵钠与依诺肝素预防骨科大置换后静脉血栓栓塞症疗效与安全性的Meta分析[J].南方医科大学学报,2013,33(3):370-375.
• [14]Wong PC,Crain EJ,Xin B,et a1.Apixaban,an oral,direct and highly selective factor Xa inhibitor:in vitro,antithrombotic and antihemostatic studies[J].J Thromb Haemost,2008,6(5):820-829.
• [15]Lassen MR,Raskob GE,Gallusa A,et a1.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement(ADVANCE-2):a randomised double-blind trial[J].Lancet,2010,375:807-815.
• [16]Michael RL,Gary ER,Alexander G,et al.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement(ADVANCE-2):a randomized double-blind trial[J].Lancet,2010,375(9717):807-815.
• [17]Michael RL,Gary ER,Alexander G,et al.Apixaban versus enoxaparin for thromboprophylaxis after hip replacement[J].Engl J Med,2010,363(26):24877-2498.
• [18]Gómez-Outes A,Terleira-Fernández AI,Suárez-Gea ML,et al.Dabigatran,rivaroxaban,or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement:systematic review,meta-analysis,and indirect treatment comparisons[J].BMJ,2012,344(24):e3675.
• [19]Shaikh N.Heparin-induced thrombocytopenia[J].Emerg Trauma Shock,2011,4(1):97-102.